

Polymorphism of amyloid-like fibrils can be defined by the concentration of seeds

Tomas Sneideris*, Katažyna Milto* and Vytautas Smirnovas

Department of Biothermodynamics and Drug Design, Vilnius University, Institute of Biotechnology, Vilnius, Lithuania

*These authors contributed equally to this work.

ABSTRACT

Prions are infectious proteins where the same protein may express distinct strains. The strains are enciphered by different misfolded conformations. Strain-like phenomena have also been reported in a number of other amyloid-forming proteins. One of the features of amyloid strains is the ability to self-propagate, maintaining a constant set of physical properties despite being propagated under conditions different from those that allowed initial formation of the strain. Here we report a cross-seeding experiment using strains formed under different conditions. Using high concentrations of seeds results in rapid elongation and new fibrils preserve the properties of the seeding fibrils. At low seed concentrations, secondary nucleation plays the major role and new fibrils gain properties predicted by the environment rather than the structure of the seeds. Our findings could explain conformational switching between amyloid strains observed in a wide variety of *in vivo* and *in vitro* experiments.

Subjects Biochemistry, Biophysics

Keywords Amyloid, Prion, Protein misfolding, Protein aggregation, Amyloid-like fibrils, Prion strain, Polymorphism, Elongation, Nucleation

INTRODUCTION

Prions are infectious particles which play the main role in a group of fatal neurodegenerative disorders, also known as the transmissible spongiform encephalopathies (TSE's). Prion diseases propagate by self-replication of a pathogenic prion isoform (PrP^{Sc}) using cellular prion protein (PrP^C) as a substrate (*Prusiner, 1998; Collinge, 2001*). Although structures of infectious forms of PrP are still only partially defined, it is known that PrP^{Sc} is rich in beta-sheet structure and demonstrates fibrillar morphology (*Sim & Caughey, 2009; Colby & Prusiner, 2011*). Different conformations of PrP^{Sc} are responsible for variations in prion disease phenotypes and are usually referred to as strains (*Safar et al., 1998*). For a long time, prion protein was the only suspected infective protein in humans; however, recently there is growing evidence that proteins in other amyloid-related diseases may spread via prion-like mechanisms (*Lundmark et al., 2002; Soto, Estrada & Castilla, 2006; Frost & Diamond, 2010; Brundin, Melki & Kopito, 2010; Eisele et al., 2010; Angot et al., 2010; Westermark & Westermark, 2010; Masuda-Suzukake et al., 2013; Eisele, 2013; Goedert et al., 2014*). Moreover, the most recent data suggest that variants of Alzheimer's disease are encoded by different strains (*Stöhr et al., 2014; Watts et al., 2014; Aguzzi, 2014*).

Submitted 19 May 2015
Accepted 1 August 2015
Published 20 August 2015

Corresponding author
Vytautas Smirnovas,
vytautas.smirnovas@bti.vu.lt

Academic editor
Vladimir Uversky

Additional Information and
Declarations can be found on
page 9

DOI 10.7717/peerj.1207

© Copyright
2015 Sneideris et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

A lot of information on possible mechanisms of amyloid-like fibril formation comes from *in vitro* studies of the aggregation kinetics (Knowles *et al.*, 2009; Arosio *et al.*, 2014; Meisl *et al.*, 2014). It is thought that four major steps are involved in fibril formation (Meisl *et al.*, 2014). In the case of spontaneous aggregation, everything starts from primary nucleation. It takes time for a group of soluble protein molecules to get together and misfold into an amyloid-like structure, which serves as a nucleus for fibrillation. Once nuclei are formed, they start elongation into fibrils by attaching soluble protein at the ends and refolding it into an amyloid-like structure. Although nucleation and elongation could be sufficient for describing fibrillation, in many cases secondary processes, such as fibril fragmentation and secondary nucleation are extremely important (Knowles *et al.*, 2009; Meisl *et al.*, 2014). Fibril fragmentation increases the number of fibril ends, which leads to faster elongation. The presence of fibrils can induce formation of new nuclei with much shorter lag times compared to primary nucleation; this is referred to as secondary nucleation (Meisl *et al.*, 2014).

How would such a mechanism of fibril formation work in the case of different amyloid strains? Strain-like structural polymorphism was observed in a number of different amyloid-forming proteins (Tanaka *et al.*, 2004; Tanaka *et al.*, 2005; Yamaguchi *et al.*, 2004; Dzwolak *et al.*, 2004; Petkova *et al.*, 2005; Jones & Surewicz, 2005; Heise *et al.*, 2005; Paravastu *et al.*, 2008; Makarava *et al.*, 2009; Colby *et al.*, 2009; Dinkel *et al.*, 2011; Jones *et al.*, 2011; Chatani *et al.*, 2012; Bousset *et al.*, 2013; Ghaemmaghami *et al.*, 2013; Cobb *et al.*, 2014; Tycko, 2014; Surmacz-Chwedoruk, Babenko & Dzwolak, 2014). To form different amyloid strains *de novo* using the same protein, different environmental conditions, such as temperature (Tanaka *et al.*, 2005), shear forces (Makarava *et al.*, 2009), concentration of denaturants (Cobb *et al.*, 2014) or co-solvents (Dzwolak *et al.*, 2004) are involved. Once nuclei are formed, they are able to carry strain-specific properties even in unfavorable environments (Dzwolak *et al.*, 2004; Petkova *et al.*, 2005; Makarava *et al.*, 2009; Cobb *et al.*, 2014; Surmacz-Chwedoruk, Babenko & Dzwolak, 2014). This indicates that environment defines different strains during primary nucleation, but affects only kinetics, not the structure, of fibrils formed via elongation. In the case of secondary nucleation, formation of new nuclei is induced by existing fibrils, but there is no experimental evidence if the structure of these nuclei is determined by the environment conditions, or by structure of the fibrils. Or in other words, can secondary nucleation be responsible for conformational switching in amyloid-like fibril strains?

MATERIALS AND METHODS

Recombinant mouse prion protein fragment (rMoPrP(89-230)) used in this study was purified and stored as described previously (Milto, Michailova & Smirnovas, 2014). Protein grade guanidine hydrochloride (GuHCl) was purchased from Carl Roth GmbH, guanidine thiocyanate (GuSCN) and other chemicals were purchased from Fisher Scientific UK.

To prepare different fibril strains, monomeric protein from a stock solution was diluted to a concentration of 0.5 mg/mL in 50 mM phosphate buffer (pH 6) containing 2 M or 4 M GuHCl, and incubated for one week at 37 °C with 220 rpm shaking (in shaker incubator

IKA KS 4000i). For seeding experiments rPrP-A^{4M} fibrils were treated for 10 min using Bandelin Sonopuls 3100 ultrasonic homogenizer equipped with MS72 tip (using 20% power, cycles of 30 s/30 s sonication/rest, total energy applied to the sample per cycle—0.36 kJ). The sample was kept on ice during the sonication. Right after the treatment, fibrils were mixed with 0.5 mg/ml of mouse prion solution in 2 M GuHCl in 50 mM phosphate buffer, pH 6, containing 50 μ M ThT. Elongation kinetics at 60 °C temperature was monitored by ThT fluorescence assay (excitation at 470 nm, emission at 510 nm) using Qiagen Rotor-Gene Q real-time analyzer (Milto, Michailova & Smirnovas, 2014). ThT fluorescence curves were normalized by dividing each point by the maximum intensity of the curve.

For denaturation assays, amyloid fibrils were resuspended to a concentration of 25 μ M in 50 mM phosphate buffer, pH 6, containing 0.5 M GuSCN and homogenized by sonication (same way as in preparation of seeds). These solutions were diluted 1:4 in a buffer containing varying concentrations of GuSCN, and incubated for 60 min at 25 °C in Maxymum RecoveryTM microtubes (Axygen Scientific, Inc., Union City, California, USA). 150 μ L of samples were mixed with 850 μ L of 100 mM phosphate buffer, pH 7, containing ThT (final concentration after dilution was 50 μ M), then each mixture was sonicated for 15 s (same conditions as described above). Fluorescence was measured at 480 nm using the excitation wavelength of 440 nm. Denaturation curves were normalized by dividing each point by the average intensity of the points in the plateau region. Fractional loss of signal at increasing denaturant concentrations corresponds to the fraction of rPrP dissociated from amyloid fibrils.

For AFM experiments, 30 μ L of the sample were deposited on freshly cleaved mica and left to adsorb for 1 min, the sample was rinsed with several mL of water and dried gently using airflow. AFM images were recorded in the Tapping-in-Air mode at a drive frequency of approximately 300 kHz, using a Dimension Icon (Bruker, Santa Barbara, California, USA) scanning probe microscope system. Aluminium-coated silicon tips (RTESPA-300) from Bruker were used as a probe.

To prepare samples for the FTIR measurements, rMoPrP aggregates were separated from the buffer by centrifugation (30 min, 15,000 g), and resuspended in D₂O, sedimentation and resuspension was repeated three times to minimize the amount of GuHCl and H₂O. After resuspension samples were homogenized by 1 min sonication (same conditions as described above). The FTIR spectra were recorded using Bruker Alpha spectrometer equipped with deuterium triglycine sulfate (DTGS) detector. For all measurements, CaF₂ transmission windows and 0.1 mm Teflon spacers were used. Spectra were recorded at room temperature. For each spectrum, 256 interferograms of 2 cm⁻¹ resolution were co-added. A corresponding buffer spectrum was subtracted from each sample spectrum. All the spectra were normalized to the same area of amide I/I' band. All data processing was performed using GRAMS software.

RESULTS

Conformational stability of PrP^{Sc} as defined by resistance to chemical denaturation has been one of the key parameters used to define differences between strains (Colby *et al.*,




Figure 1 Denaturation profiles of rPrP-A^{2M} and rPrP-A^{4M} fibrils in GuSCN reveal different conformational stabilities. Standard errors calculated from 6 measurements using Student's *t*-distribution at $P = 0.05$.

2009). Different strains of recombinant mammalian prion protein amyloid-like fibrils made in 2 and 4 M guanidine hydrochloride (rPrP-A^{2M} and rPrP-A^{4M}, respectively) were thoroughly characterized by Surewicz group (Cobb *et al.*, 2014). We used recombinant N-terminally truncated mouse prion protein (rMoPrP(89-230)) to create rPrP-A^{2M} and rPrP-A^{4M} strains of amyloid-like fibrils. Similar to recent data on recombinant human PrP (Cobb *et al.*, 2014), rMoPrP fibrils formed in 2 and 4 M guanidine hydrochloride (GuHCl) have different conformational stability (Fig. 1). Due to the fact that rPrP-A^{4M} fibrils could not be fully denatured using even 7.5 M GuHCl (Cobb *et al.*, 2014), a denaturation assay using a more strongly chaotropic salt, guanidine thiocyanate (GuSCN) was performed. Midpoint of denaturation of rPrP-A^{2M} is at ~1.8 M GuSCN and rPrP-A^{4M} is at ~3 M GuSCN, respectively. This difference served as a simple, unbiased marker of different strains in further experiments.

In our previous work we have described elongation kinetics at different temperatures and GuHCl concentrations, using rPrP-A^{2M} as a seed (Mito, Michailova & Smirnovas, 2014). It was not possible to get reliable data above 2.5 M GuHCl due to depolymerization of rPrP-A^{2M}. Thus only one way cross-seeding is possible for rPrP-A^{2M} and rPrP-A^{4M} strains. We followed cross-seeding kinetics using different concentrations of seeds. As seen in Fig. 2A, five percent seeds led to fast growth of amyloid-like fibrils from the very beginning, suggesting fast fibril elongation. At 1% seed volume (Fig. 2B) elongation is slower, but after some time the rate of aggregation explodes. At a lower concentration of seeds (Fig. 2C) elongation is very slow and the curve looks sigmoidal, as usually seen in case of spontaneous fibrillation; however in absence of seeds no aggregation was detected within the experimental timeframe. Fitting data suggests that the observed process can be




Figure 2 Concentration of seeds determines the mechanism of aggregation and stability of the final strain. Different amounts of rPrP-A^{4M} fibrils (sonicated for 300 s) were added to the solution of rMoPrP, prepared in 2 M GuHCl, 50 mM phosphate buffer, pH6. The kinetics was followed at 60 °C using Thioflavin T (ThT) fluorescence assay, five data repeats at each seed concentration plotted in (A–C). No change of ThT fluorescence was observed in samples without seeds. Denaturation profiles in GuSCN reveal different conformational stabilities of formed fibrils (D–F). Standard errors calculated from 6 measurements using Student's *t*-distribution at $P = 0.05$.

attributed to fibril-induced secondary nucleation (see [Supplemental Information](#)). The fibril denaturation assay ([Fig. 2D](#)) revealed that stability of fibrils formed in the presence of 5% seeds (midpoint at ~ 2.9 M GuSCN) is very similar to rPrP-A^{4M} strain, which was used as a seed. At 1% seed volume ([Fig. 2E](#)), stability of fibrils is lower (midpoint at ~ 2.2 M GuSCN), and at 0.2% of seeds ([Fig. 2F](#)) it is the same (midpoint at ~ 1.8 M GuSCN) as the rPrP-A^{2M} strain. This allows hypothesizing that fibrils initiated by secondary nucleation do not follow the seeding template, despite using template fibrils as nucleation sites.

AFM analysis did not reveal any major differences between rPrP-A^{4M} and rPrP-A^{2M} strains ([Figs. 3A](#) and [3B](#)). In both cases fibril diameters range from 4 to 16 nm, however thicker fibrils are more often in samples of rPrP-A^{2M} strains. This difference is more




Figure 3 AFM images of rMoPrP amyloid-like aggregates. (A) and (B) show fibrils of rPrP-A^{4M} and rPrP-A^{2M} strains, (C) and (D) show fibrils formed during cross-seeding in the presence of 5% and 0.2% seeds, respectively.

obvious when comparing fibrils formed in presence of 5% and 0.2% seeds (Figs. 3C and 3D). The majority of fibrils formed in presence of high amount of seeds are 4–8 nm in diameter, while these formed at low seed concentration are usually 8–16 nm.

FTIR spectra of rMoPrP amyloid-like fibrils display major band in the amide I/I' region, corresponding to beta-sheet structure with subtle difference in band frequencies between rPrP-A^{4M} and rPrP-A^{2M} strains (Fig. 4). The spectrum of rPrP-A^{4M} strain is very similar to the spectrum of fibrils, prepared in the presence of 5% seeds; both show peak maxima at $\sim 1,620\text{ cm}^{-1}$. The spectrum of rPrP-A^{2M} strain and the spectrum of fibrils, prepared in the presence of 0.2% seeds show peak maxima at $\sim 1,624\text{ cm}^{-1}$. This data serve as additional confirmation that propagation of the strain-specific structure depends on the amount of seeds and possibly on the mechanism of aggregation.

In our previous work we have demonstrated the impact of sonication on the elongation kinetics of PrP fibrils (Mito, Michailova & Smirnovas, 2014). Comparison of microscopy data before (Fig. 3A) and after (Fig. 5) sonication suggests that the main effect of sonication is breaking fibrils into shorter pieces, thus increasing number of fibril ends.




Figure 4 FTIR spectra of rPrP amyloid-like fibrils.




Figure 5 AFM images of rPrP-A^{4M} fibrils after 300 s (A) and 30 s (B) sonication.

As seen in Figs. 6A and 6B, in case of shorter (or in the absence of) sonication, kinetic curves have sigmoidal shapes, similar as in case of lower amount of longer-sonicated seeds. Fibrils formed in the presence of 30 s sonicated seeds (Fig. 6C) are more stable (midpoint at ~ 2.8 M GuSCN) compared to the fibrils formed in presence of unsonicated seeds (midpoint at ~ 2.3 M GuSCN).




Figure 6 Effect of sonication on the kinetics of aggregation (A–B) and stability of formed fibrils (C–D). The same amount of seeds (5%) was used in all experiments. Five data repeats plotted in (A) and (B). Standard errors calculated from 6 measurements using Student's t -distribution at $P = 0.05$.

DISCUSSION

Taken together the data with different seed concentrations (Fig. 2), and sonication times (Fig. 6), show that stability of fibrils is dependent on the kinetics. Different processes in fibril formation leads to the mixture of rPrP-A^{4M} and rPrP-A^{2M} fibril populations in all samples, and different proportions of two strains determine their denaturation profiles. Increase of fibril ends leads to shorter lag times and faster elongation rates, and to the bigger proportion of more stable fibrils. In fact, we cannot exclude the impact of fibril surface as a catalyzer of secondary nucleation. Larger super-structures can be disrupted by sonication thus releasing more fibril surface. We haven't found large clumps using microscopy, but the possibility of larger aggregates is suggested by the decline of final fluorescence in samples where mild or no sonication was used. Larger aggregates used as seeds grow further and may settle out of solution leading to the decrease of ThT fluorescence.

It is interesting to compare reproducibility of kinetic curves at different conditions. At highest amount of seeds the data is extremely reproducible (Fig. 2A), which is common for fibril elongation reactions. In case of lowest seed concentration (Fig. 2C) it is also relatively good; however it is poor at moderate seed concentration (Fig. 2B) or in case of unsonicated seeds (Fig. 6B). Nucleation is a stochastic event and the reproducibility goes down with the decrease of the monomer concentration. Due to the elongation of fibrils, average monomer concentration available for nucleation in the presence of 1% seeds is lower than in case of 0.2% seeds, thus it can serve as an explanation of the worse reproducibility.

Amyloid strain switching has been observed in animal studies (*Bartz et al., 2000; Asante et al., 2002; Lloyd et al., 2004; Ghaemmaghami et al., 2013*), cell culture (*Li et al., 2010*), and experiments *in vitro* (*Castilla et al., 2008; Makarava et al., 2009; Surmacz-Chwedoruk, Babenko & Dzwolak, 2014*). Two possibilities are suggested to explain this phenomenon (*Collinge & Clarke, 2007; Cobb & Surewicz, 2009*). The first one describes coexistence of multiple structures in the infective material, when only the dominant type would be recognized experimentally; however, upon transmission to different host, the minor population may self-propagate much better and become dominant, reflected in the change of strain properties. Recently this way of amyloid strain switching was demonstrated for insulin fibrils *in vitro* (*Surmacz-Chwedoruk, Babenko & Dzwolak, 2014*). The second possibility suggested that sometimes host protein can adopt amyloid conformations distinct from the heterologous template. The Baskakov group demonstrated adaptive conformational switching within individual fibrils as a possible mechanism for such change (*Makarava et al., 2009*). Our data suggests a possibility of strain switching via secondary nucleation pathways. Moreover, secondary nucleation could explain switching of strains in absence of species barrier, for example in case of recently described Darwinian evolution of prions in cell culture, which showed strain mutations within a single host protein (*Li et al., 2010*) or in case of protein misfolding cyclic amplification (PMCA) of recombinant PrP (*Smirnovas et al., 2009*). In summary, we hypothesize that continuous propagation or switching between amyloid strains may be determined by the mechanism of replication in addition to the environment. In cases when a species barrier or environmental barrier stops or slows down fibril elongation, there is the possibility of secondary nucleation events to seed the formation of different strains. The mechanism is dependent on the concentration of fibrils, which opens up a new dimension in cross-species and cross-environment seeding/infection experiments.

We would like to acknowledge that part of the described kinetic profiles differs from the general fibrillation kinetics, normally observed in the field. Thus, in the absence of supporting investigations of different systems, we would like to stress that all our findings may be limited to the described system and any extrapolation to other amyloid proteins and/or other conditions of fibrillation needs an additional experimental evidence.

ACKNOWLEDGEMENTS

The authors thank Prof. Witold Surewicz for sharing MoPrP(89-230) plasmid, Dr. Marija Jankunec for help with AFM, and Dr. Jonathan G. Cannon for critical reading of the manuscript.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This research was funded by a grant (No. MIP-030/2012) from the Research Council of Lithuania. VS was supported by a Marie Curie Career Integration Grant 293476. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

Research Council of Lithuania: MIP-030/2012.

Marie Curie Career Integration Grant: 293476.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Tomas Sneideris and Katažyna Milto conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, reviewed drafts of the paper.
- Vytautas Smirnovas conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.1207#supplemental-information>.

REFERENCES

- Aguzzi A. 2014.** Neurodegeneration: alzheimer's disease under strain. *Nature* 512:32–34 DOI 10.1038/512032a.
- Angot E, Steiner JA, Hansen C, Li JY, Brundin P. 2010.** Are synucleinopathies prion-like disorders? *The Lancet Neurology* 9:1128–1138 DOI 10.1016/S1474-4422(10)70213-1.
- Arosio P, Cukalevski R, Frohm B, Knowles TPJ, Linse S. 2014.** Quantification of the concentration of Abeta42 propagons during the lag phase by an amyloid chain reaction assay. *Journal of the American Chemical Society* 136:219–225 DOI 10.1021/ja408765u.
- Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I, Wood AL, Welch J, Hill AF, Lloyd SE, Wadsworth JDF, Collinge J. 2002.** BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. *EMBO Journal* 21:6358–6366 DOI 10.1093/emboj/cdf653.
- Bartz JC, Bessen RA, McKenzie D, Marsh RF, Aiken JM. 2000.** Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy. *Journal of Virology* 74:5542–5547 DOI 10.1128/JVI.74.12.5542-5547.2000.
- Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A, Meier BH, Melki R. 2013.** Structural and functional characterization of two alpha-synuclein strains. *Nature Communications* 4:Article 2575 DOI 10.1038/ncomms3575.
- Brundin P, Melki R, Kopito R. 2010.** Prion-like transmission of protein aggregates in neurodegenerative diseases. *Nature Reviews. Molecular Cell Biology* 11:301–307 DOI 10.1038/nrm2873.
- Castilla J, Gonzalez-Romero D, Saá P, Morales R, De Castro J, Soto C. 2008.** Crossing the species barrier by PrPSc replication *in vitro* generates unique infectious prions. *Cell* 134:757–768 DOI 10.1016/j.cell.2008.07.030.

- Chatani E, Yagi H, Naiki H, Goto Y. 2012.** Polymorphism of beta 2-microglobulin amyloid fibrils manifested by ultrasonication-enhanced fibril formation in trifluoroethanol. *Journal of Biological Chemistry* **287**:22827–22837 DOI [10.1074/jbc.M111.333310](https://doi.org/10.1074/jbc.M111.333310).
- Cobb NJ, Apostol MI, Chen S, Smirnovas V, Surewicz WK. 2014.** Conformational stability of mammalian prion protein amyloid fibrils is dictated by a packing polymorphism within the core region. *Journal of Biological Chemistry* **289**:2643–2650 DOI [10.1074/jbc.M113.520718](https://doi.org/10.1074/jbc.M113.520718).
- Cobb NJ, Surewicz WK. 2009.** Prion diseases and their biochemical mechanisms. *Biochemistry* **48**:2574–2585 DOI [10.1021/bi900108v](https://doi.org/10.1021/bi900108v).
- Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, Prusiner SB. 2009.** Design and construction of diverse mammalian prion strains. *Proceedings of the National Academy of Sciences of the United States of America* **106**:20417–20422 DOI [10.1073/pnas.0910350106](https://doi.org/10.1073/pnas.0910350106).
- Colby DW, Prusiner SB. 2011.** Prions. *Cold Spring Harbor Perspectives in Biology* **3**:1–22 DOI [10.1101/cshperspect.a006833](https://doi.org/10.1101/cshperspect.a006833).
- Collinge J. 2001.** Prion diseases of humans and animals: their causes and molecular basis. *Annual Review of Neuroscience* **24**:519–550 DOI [10.1146/annurev.neuro.24.1.519](https://doi.org/10.1146/annurev.neuro.24.1.519).
- Collinge J, Clarke AR. 2007.** A general model of prion strains and their pathogenicity. *Science* **318**:930–936 DOI [10.1126/science.1138718](https://doi.org/10.1126/science.1138718).
- Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M. 2011.** Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. *Biochemistry* **50**:4330–4336 DOI [10.1021/bi2004685](https://doi.org/10.1021/bi2004685).
- Dzwolak W, Smirnovas V, Jansen R, Winter R. 2004.** Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study. *Protein Science: a Publication of the Protein Society* **13**:1927–1932 DOI [10.1110/ps.03607204](https://doi.org/10.1110/ps.03607204).
- Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. 2010.** Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. *Science* **330**:980–982 DOI [10.1126/science.1194516](https://doi.org/10.1126/science.1194516).
- Eisele YS. 2013.** From soluble Abeta to progressive Abeta aggregation: could prion-like templated misfolding play a role? *Brain Pathology* **23**:333–341 DOI [10.1111/bpa.12049](https://doi.org/10.1111/bpa.12049).
- Frost B, Diamond MI. 2010.** Prion-like mechanisms in neurodegenerative diseases. *Nature Reviews. Neuroscience* **11**:155–159 DOI [10.1038/nrn2786](https://doi.org/10.1038/nrn2786).
- Ghaemmaghami S, Colby DW, Nguyen HOB, Hayashi S, Oehler A, Dearmond SJ, Prusiner SB. 2013.** Convergent replication of mouse synthetic prion strains. *American Journal of Pathology* **182**:866–874 DOI [10.1016/j.ajpath.2012.11.038](https://doi.org/10.1016/j.ajpath.2012.11.038).
- Goedert M, Falcon B, Clavaguera F, Tolnay M. 2014.** Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. *Current Neurology and Neuroscience Reports* **14**:Article 495 DOI [10.1007/s11910-014-0495-z](https://doi.org/10.1007/s11910-014-0495-z).
- Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M. 2005.** Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. *Proceedings of the National Academy of Sciences of the United States of America* **102**:15871–15876 DOI [10.1073/pnas.0506109102](https://doi.org/10.1073/pnas.0506109102).
- Jones EM, Surewicz WK. 2005.** Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. *Cell* **121**:63–72 DOI [10.1016/j.cell.2005.01.034](https://doi.org/10.1016/j.cell.2005.01.034).
- Jones EM, Wu B, Surewicz K, Nadaud PS, Helmus JJ, Chen S, Jaroniec CP, Surewicz WK. 2011.** Structural polymorphism in amyloids: new insights from studies with Y145Stop prion protein fibrils. *Journal of Biological Chemistry* **286**:42777–42784 DOI [10.1074/jbc.M111.302539](https://doi.org/10.1074/jbc.M111.302539).

- Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. 2009. An analytical solution to the kinetics of breakable filament assembly. *Science* 326:1533–1537 DOI 10.1126/science.1178250.
- Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. 2010. Darwinian evolution of prions in cell culture. *Science* 327:869–872 DOI 10.1126/science.1183218.
- Lloyd SE, Linehan JM, Desbruslais M, Joiner S, Buckell J, Brandner S, Wadsworth JDF, Collinge J. 2004. Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. *Journal of General Virology* 85:2471–2478 DOI 10.1099/vir.0.79889-0.
- Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A, Westermark P. 2002. Transmissibility of systemic amyloidosis by a prion-like mechanism. *Proceedings of the National Academy of Sciences of the United States of America* 99:6979–6984 DOI 10.1073/pnas.092205999.
- Makarava N, Ostapchenko VG, Savtchenko R, Baskakov IV. 2009. Conformational switching within individual amyloid fibrils. *Journal of Biological Chemistry* 284:14386–14395 DOI 10.1074/jbc.M900533200.
- Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M. 2013. Prion-like spreading of pathological α -synuclein in brain. *Brain* 136:1128–1138 DOI 10.1093/brain/awt037.
- Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard JB, Cohen SIA, Dobson CM, Linse S, Knowles TPJ. 2014. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the A β 40 and A β 42 peptides. *Proceedings of the National Academy of Sciences of the United States of America* 111:9384–9389 DOI 10.1073/pnas.1401564111.
- Milto K, Michailova K, Smirnovas V. 2014. Elongation of mouse prion protein amyloid-like fibrils: effect of temperature and denaturant concentration. *PLoS ONE* 9:e94469 DOI 10.1371/journal.pone.0094469.
- Paravastu AK, Leapman RD, Yau W-M, Tycko R. 2008. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. *Proceedings of the National Academy of Sciences of the United States of America* 105:18349–18354 DOI 10.1073/pnas.0806270105.
- Petkova AT, Leapman RD, Guo Z, Yau W-M, Mattson MP, Tycko R. 2005. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. *Science* 307:262–265 DOI 10.1126/science.1105850.
- Prusiner SB. 1998. Prions. *Proceedings of the National Academy of Sciences of the United States of America* 95:13363–13383 DOI 10.1073/pnas.95.23.13363.
- Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. 1998. Eight prion strains have PrP(Sc) molecules with different conformations. *Nature Medicine* 4:1157–1165 DOI 10.1038/2654.
- Sim VL, Caughey B. 2009. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. *Neurobiology of Aging* 30:2031–2042 DOI 10.1016/j.neurobiolaging.2008.02.016.
- Smirnovas V, Kim J II, Lu X, Atarashi R, Caughey B, Surewicz WK. 2009. Distinct structures of scrapie prion protein (PrPSc)-seeded versus spontaneous recombinant prion protein fibrils revealed by hydrogen/deuterium exchange. *Journal of Biological Chemistry* 284:24233–24241 DOI 10.1074/jbc.M109.036558.
- Soto C, Estrada L, Castilla J. 2006. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. *Trends in Biochemical Sciences* 31:150–155 DOI 10.1016/j.tibs.2006.01.002.
- Stöhr J, Condello C, Watts JC, Bloch L, Oehler A, Nick M, DeArmond SJ, Giles K, DeGrado WF,

- Prusiner SB. 2014.** Distinct synthetic A β prion strains producing different amyloid deposits in bigenic mice. *Proceedings of the National Academy of Sciences of the United States of America* **111**:2–7 DOI [10.1073/pnas.1408968111](https://doi.org/10.1073/pnas.1408968111).
- Surmacz-Chwedoruk W, Babenko V, Dzwolak W. 2014.** Master and slave relationship between two types of self-propagating insulin amyloid fibrils. *The Journal of Physical Chemistry B* **118**:13582–13589 DOI [10.1021/jp510980b](https://doi.org/10.1021/jp510980b).
- Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. 2004.** Conformational variations in an infectious protein determine prion strain differences. *Nature* **428**:323–328 DOI [10.1038/nature02392](https://doi.org/10.1038/nature02392).
- Tanaka M, Chien P, Yonekura K, Weissman JS. 2005.** Mechanism of cross-species prion transmission: an infectious conformation compatible with two highly divergent yeast prion proteins. *Cell* **121**:49–62 DOI [10.1016/j.cell.2005.03.008](https://doi.org/10.1016/j.cell.2005.03.008).
- Tycko R. 2014.** Physical and structural basis for polymorphism in amyloid fibrils. *Protein Science: a Publication of the Protein Society* **23**:1528–1539 DOI [10.1002/pro.2544](https://doi.org/10.1002/pro.2544).
- Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB. 2014.** Serial propagation of distinct strains of A β prions from alzheimer's disease patients. *Proceedings of the National Academy of Sciences* **111**:10323–10328 DOI [10.1073/pnas.1408900111](https://doi.org/10.1073/pnas.1408900111).
- Westermarck GT, Westermarck P. 2010.** Prion-like aggregates: infectious agents in human disease. *Trends in Molecular Medicine* **16**:501–507 DOI [10.1016/j.molmed.2010.08.004](https://doi.org/10.1016/j.molmed.2010.08.004).
- Yamaguchi KI, Katou H, Hoshino M, Hasegawa K, Naiki H, Goto Y. 2004.** Core and heterogeneity of β 2-microglobulin amyloid fibrils as revealed by H/D exchange. *Journal of Molecular Biology* **338**:559–571 DOI [10.1016/j.jmb.2004.02.067](https://doi.org/10.1016/j.jmb.2004.02.067).